Showing results (11-20 of 19) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
ACS Medicinal Chemistry Letters|August 18, 2022
Optimization of hERG and Pharmacokinetic Properties for Basic Dihydro-8H-purin-8-one Inhibitors of DNA-PKFrederick W Goldberg, Attilla K T Ting, David Beattie, et al.Biomedicines|February 25, 2023
Impaired Function of Solute Carrier Family 19 Leads to Low Folate Levels and Lipid Droplet Accumulation in HepatocytesAinara Cano, Mercedes Vazquez-Chantada, Javier Conde-Vancells, et al.Journal of Medicinal Chemistry|April 26, 2021
Fragment-Based Design of a Potent MAT2a Inhibitor and in Vivo Evaluation in an MTAP Null Xenograft ModelClaudia De Fusco, Marianne Schimpl, Ulf Börjesson, et al.Nature Communications|October 28, 2020
A protein tertiary structure mimetic modulator of the Hippo signalling pathwayHélène Adihou, Ranganath Gopalakrishnan, Tim Förster, et al.Journal of Medicinal Chemistry|May 22, 2026
Use of Human Dose Prediction Metrics to Enable Discovery of AZD3470, an MTA-Cooperative PRMT5 Inhibitor in Clinical EvaluationJames M Smith, Bernard Barlaam, David Beattie, et al.Nature Communications|November 9, 2019
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activityJacqueline H L Fok, Antonio Ramos-Montoya, Mercedes Vazquez-Chantada, et al.Journal of Medicinal Chemistry|March 11, 2024
Development of a Series of Pyrrolopyridone MAT2A InhibitorsStephen J Atkinson, Sharan K Bagal, Argyrides Argyrou, et al.Hepatology (Baltimore, Md.)|September 11, 2012
Solute carrier family 2 member 1 is involved in the development of nonalcoholic fatty liver diseaseMercedes Vazquez-Chantada, Aintzane Gonzalez-Lahera, Ibon Martinez-Arranz, et al.Journal of Medicinal Chemistry|July 31, 2024
Discovery and In Vivo Efficacy of AZ-PRMT5i-1, a Novel PRMT5 Inhibitor with High MTA CooperativityJames M Smith, Bernard Barlaam, David Beattie, et al.Pageof 2